Research programme: complement component 5 inhibitors - EyePoint Pharmaceuticals/Rallybio
Alternative Names: Research programme: C5 inhibitors - EyePoint Pharmaceuticals/RallybioLatest Information Update: 31 Mar 2023
At a glance
- Originator EyePoint Pharmaceuticals; Rallybio
- Class Eye disorder therapies
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Age-related macular degeneration